The marine-derived oligosaccharide sulfate MS80, a novel transforming growth factor b1 inhibitor, reverses epithelial mesenchymal transition induced by transforming growth factor-b1 and suppresses tumor metastasiss

Journal of Pharmacology and Experimental Therapeutics

Volumn 359, Issue 1, 2016, Pages 54-61

  Zhou, Ji ^a   You, Wenjie ^b   Sun, Guangqiang ^a   Li, Yixuan ^a   Chen, Bi ^b   Ai, Jing ^a   Jiang, Handong ^b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; MARINE DERIVED OLIGOSACCHARIDE SULFATE; OLIGOSACCHARIDE; PROTEIN INHIBITOR; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; MS80 OLIGOSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER CELL LINE; CD8+ T LYMPHOCYTE; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; IN VITRO STUDY; LUNG CANCER CELL LINE; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SPLEEN CELL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL MOTION; CELL TRANSFORMATION; DRUG EFFECTS; HUMAN; IMMUNOLOGY; METABOLISM; METASTASIS; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OLIGOSACCHARIDES; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84988663763     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.234799     Document Type: Article

References (37)

1. Akhurst RJ and Hata A (2012) Targeting the TGFb signalling pathway in disease. Nat Rev Drug Discov 11:790-811.
2. Ao M, Williams K, Bhowmick NA, and Hayward SW (2006) Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res 66:8007-8016.
3. Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A, et al. (2002) Identification of novel inhibitors of the transforming growth factor b1 (TGF-b1) type 1 receptor (ALK5). J Med Chem 45:999-1001.
4. Derynck R, Akhurst RJ, and Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117-129.
5. Do TV, Kubba LA, Du H, Sturgis CD, and Woodruff TK (2008) Transforming growth factor-b1, transforming growth factor-b2, and transforming growth factor-b3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res 6:695-705.
6. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, and Tang ZY (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25:2586-2593.
7. Garrison K, Hahn T, Lee WC, Ling LE, Weinberg AD, and Akporiaye ET (2012) The small molecule TGF-b signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol Immunother 61:511-521.
8. Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, et al. (2006) Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res 12:4315-4330.
9. Gorelik L and Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7: 1118-1122.
10. Grau AM, Wen W, Ramroopsingh DS, Gao YT, Zi J, Cai Q, Shu XO, and Zheng W (2008) Circulating transforming growth factor-beta-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 112: 335-341.
11. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
12. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, and Okumura K (2001) Transforming growth factor-b1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91:964-971.
13. Heldin CH, Landström M, and Moustakas A (2009) Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 21:166-176.
14. Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, et al. (2015) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 9:4479-4499.
15. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, and Hill CS (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-b superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62:65-74.
16. Jiang HD and Guan HS (2009) MS80, a novel sulfated oligosaccharide, inhibits pulmonary fibrosis by targeting TGF-b1 both in vitro and in vivo. Acta Pharmacol Sin 30:973-979.
17. Kang Y and Massagué J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118:277-279.
18. Langenskiöld M, Holmdahl L, Falk P, Angenete E, and Ivarsson ML (2008) Increased TGF-beta 1 protein expression in patients with advanced colorectal cancer. J Surg Oncol 97:409-415.
19. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, et al. (2002) Inhibition of transforming growth factor (TGF)-b1-induced extracellular matrix with a novel inhibitor of the TGF-b type I receptor kinase activity: SB-431542. Mol Pharmacol 62:58-64.
20. Li MO, Wan YY, Sanjabi S, Robertson AK, and Flavell RA (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24:99-146.
21. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, and Lee C (2007) Tumor evasion of the immune system by converting CD41 CD252 T cells into CD41 CD251 T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178:2883-2892.
22. Maruyama T, Li J, Vaque JP, Konkel JE, Wang W, Zhang B, Zhang P, Zamarron BF, Yu D, Wu Y, et al. (2011) Control of the differentiation of regulatory T cells and TH 17 cells by the DNA-binding inhibitor Id3. Nat Immunol 12:86-95.
23. Mehlen P and Puisieux A (2006) Metastasis: a question of life or death. Nat Rev Cancer 6:449-458.
24. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, and Chiao PJ (2008) LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7:829-840.
25. Park CY, Min KN, Son JY, Park SY, Nam JS, Kim DK, and Sheen YY (2014) An novel inhibitor of TGF-b type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition. Cancer Lett 351:72-80.
26. Polyak K and Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265-273.
27. Rausch MP, Hahn T, Ramanathapuram L, Bradley-Dunlop D, Mahadevan D, Mercado-Pimentel ME, Runyan RB, Besselsen DG, Zhang X, Cheung HK, et al. (2009) An orally active small molecule TGF-b receptor I antagonist inhibits the growth of metastatic murine breast cancer. Anticancer Res 29:2099-2109.
28. Son JY, Park SY, Kim SJ, Lee SJ, Park SA, Kim MJ, Kim SW, Kim DK, Nam JS, and Sheen YY (2014) EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis. Mol Cancer Ther 13:1704-1716.
29. Teicher BA (2007) Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 13:6247-6251.
30. Terabe M, Ambrosino E, Takaku S, O'Konek JJ, Venzon D, Lonning S, McPherson JM, and Berzofsky JA (2009) Synergistic enhancement of CD81 T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin Cancer Res 15:6560-6569.
31. Thiery JP, Acloque H, Huang RY, and Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871-890.
32. Thomas DA and Massagué J (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8:369-380.
33. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu Y-W, Platten M, Herrlinger U, et al. (2004) SD-208, a novel transforming growth factor b receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64:7954-7961.
34. Wang X, Chu J, Wen CJ, Fu SB, Qian YL, Wo Y, Wang C, and Wang DR (2015) Functional characterization of TRAP1-like protein involved in modulating fibrotic processes mediated by TGF-b/Smad signaling in hypertrophic scar fibroblasts. Exp Cell Res 332:202-211.
35. Witham TF, Villa L, Yang T, Pollack IF, Okada H, Robbins PD, and Chambers WH (2003) Expression of a soluble transforming growth factor-beta (TGFb) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J Neurooncol 64:63-69.
36. Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U, et al. (2011) Blockade of TGF-b signaling by the TGFbR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 71:7155-7167.
37. Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K, et al. (2010) Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res 16:1191-1205.